Vertex submits application for hepatitis C drug

Vertex Pharmaceuticals Inc. said today that it has completed the submission of a New Drug Application that seeks regulatory approval for telaprevir, a hepatitis C drug candidate with the potential to generate billions of dollars in annual revenue.

The submission includes a request to the US Food and Drug Administration to reduce the FDA’s review time from 10 months to six months, Cambridge-based Vertex said in a press release.